Результаты поиска

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report.

Rheumatoid arthritis patients might experience several hematologic complications. The development of myelodysplastic syndrome is not clearly associated with RA, even though it has been described in some patients with pre-existing disease. There are only few data available in the literature concerning the therapeutic approach of such patients. Herein, we report a case of RA complicated with progressive MDS, successfully treated with rituximab and lenalidomide combination therapy.

От эмпирического лечения к точному вмешательству: библиометрический анализ нейропсихиатрической системной волшебной системы с использованием нескольких баз данных (Erithematosus)2006-2025).

ЦЕЛЬ: Нейропсихиатрическая системная волчанка (NPSLE) представляет собой серьезное и сложное осложнение системного волчанка, которое влияет на принятие диагностических решений и стратегии лечения. Однако временнóе развитие основанных на фактических данных диагностических и терапевтических парадигм, а также сохраняющиеся клинические узкие места не были в полной мере охарактеризованы. МЕТОДЫ: Мы провели всеобъемлющий библиометрический анализ 1,569 Публикации, связанные с ЯИЭ, взяты из " Web of Science Core Collection " и " Scopus " 2006 и 2025. Кроме того, были включены соотв

Совпадение в полном тексте источника
… Paper | Global total citations | Normalized TC | IF(2025) FANOURIAKIS A, 2019, ANN RHEUM DIS | 1448 | 33.57 | 20.6 BERTSIAS GK, 2008, ANN. RHEUM. DIS. | 615 | 12.27 | 20.6 D’CRUZ DP, 2007, LANCET | 608 | 9.87 | 88.5 BERTSIAS GK, 2010, ANN RHEUM DIS | 590 | 12.17 | 20.6 ANTONELLI A, 2014, AUTOIMMUN. … RHEUM. …

Sheng-Jiang Powder Alleviates Th17/Treg Immune Imadium of Experimental Autoimune Encephalomyelitis путем регулирования метаболизма жирных кислот.

Множественный склероз (MS) является одной из главных причин инвалидности среди молодежи, и иммунный дисбаланс между клеткой Т 17 (Th17) и клетками регулирования Т (Tregs) играет решающую роль в ее патогенезе. В настоящее время лечение MS в значительной степени зависит от иммунодепрессивных препаратов или глюкокортикоидов, которые часто имеют побочные эффекты и недостатки в эффективности. Порошок Шэн Цзян (SJP) — традиционная китайская медицина — продемонстрировал антивоспалительные эффекты и может предложить новый терапевтический вариант для MS.АИМ: Цель этого исследования заключалась в изучен

Совпадение в полном тексте источника
… Among these, Rheum officinale Baill . and its active ingredients exhibit significant anti-inflammatory effects. … Materials and Methods Medicine Preparation The SJP medicinal granules, prepared and supplied by Guangdong Yifang Pharmaceutical Co., Ltd., comprised Rheum officinale Baill . …

The Role of Fc-like Receptor 3 in the Pathophysiology of Rheumatoid Arthritis.

The pathogenesis of rheumatoid arthritis involves a complex interplay of genetic predisposition, environmental factors, and autoimmune mechanisms that lead to chronic inflammation of the synovial membrane. Fc-like receptor 3 (FcRL3) is a receptor encoded by the FCRL3 gene, located on the long arm of chromosome 1 at 1q23.1. Polymorphisms in the promoter region of FCRL3, rather than elsewhere in the gene, primarily affect the level of protein expression, which is of clinical significance. Understanding the structure of FcRL3, particularly in the context of genetic variants, is therefore importan…

Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients.

Osteonecrosis (ON) is a complex and multifactorial complication of systemic lupus erythematosus (SLE). ON is a devastating condition that causes severe pain and compromises the quality of life. The prevalence of ON in SLE patients is variable, ranging from 1.7% to 52%. However, the pathophysiology and risk factors for ON in patients with SLE have not yet been fully determined. Several mechanisms for SLE patients' propensity to develop ON have been proposed. Glucocorticoid is a widely used therapeutic option for SLE patients and high-dose glucocorticoid therapy in SLE patients is strongly assoc

Совпадение в полном тексте источника
… Semin Arthritis Rheum . 2002 ; 32 : 94 ‐ 124 . 12430099 10 Adesina OO , Neumayr LD . Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management . … Semin Arthritis Rheum . 2003 ; 32 : 370 ‐ 377 . 12833245 10.1053/sarh.2002.50003 115 Ruiz‐Arruza I , et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus . …

Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.

INTRODUCTION: The clinical characteristics of autoantibody-mediated autoimmune diseases are diverse. Yet, medical treatment and the associat … 18 treatment-refractory patients suffering from myasthenia gravis, systemic lupus erythematosus and rheumatoid arthritis that will be treated with bortezomib add-on to pre-existing therapy. Primary endpoint is the change in autoantibody levels 6 months after therapy. Secondary endpoints include concomitant medication, disease-specific clinical scores an …

Identification of Common Differentially Expressed Genes and Potential Therapeutic Targets in Ulcerative Colitis and Rheumatoid Arthritis.

Ulcerative colitis (UC) and rheumatoid arthritis (RA) are immune-mediated inflammatory diseases (IMIDs) with similar symptoms and common genomics. However, the relationship between UC and RA has not been investigated thoroughly. Therefore, this study aimed to establish the differentially expressed genes (DEGs) and potential therapeutic targets in UC and RA. Three microarray datasets (GSE38713, GSE1919, and GSE12251) were selected from the Gene Expression Omnibus (GEO) database for analysis. We used R software to identify the DEGs and performed enrichment analyses. Search Tool for the Retrieval…

Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?

Clinicians involved in the treatment of inflammatory bowel disease (IBD) increasingly come across patients with current or previous history … These data combined with data arising from treatment registries from other immune disorders such as rheumatoid arthritis are providing evidence of relative risks and safety profiles of these agents in the setting of active or prior cancer. Data from transplant literature give an indication for providing a drug-holiday period in patients with treated can …

Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.

Precision medicine has become a cornerstone in modern therapeutic strategies, with nucleic acid aptamers emerging as pivotal tools due to their unique properties. These oligonucleotide fragments, selected through the Systematic Evolution of Ligands by Exponential Enrichment process, exhibit high affinity and specificity toward their targets, such as DNA, RNA, proteins, and other biomolecules. Nucleic acid aptamers offer significant advantages over traditional therapeutic agents, including superior biological stability, minimal immunogenicity, and the capacity for universal chemical modificatio

Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment.

Systemic sclerosis (SSc, scleroderma) is a severe disease characterized by peripheral microcirculation abnormalities manifesting with Raynaud's phenomenon, nailfold videocapillaroscopic (NVC) changes, and even ischemic digital ulcers (DUs) that are often refractory to treatments. In the wake of previously described associations between the circulating levels of soluble junctional adhesion molecules (sJAMs) and SSc clinical features, here, we measured sJAM-A and sJAM-C levels by enzyme-linked immunosorbent assay in serum samples from a large case series of 110 SSc patients and 85 healthy contro

Совпадение в полном тексте источника
… Arthritis Rheum. 2013;65:247–257. doi: 10.1002/art.37712. 8. Bruni C., Frech T., Manetti M., Rossi F.W., Furst D.E., De Paulis A., Rivellese F., Guiducci S., Matucci-Cerinic M., Bellando-Randone S. … Rheum. Dis. 2005;64:1165–1173. doi: 10.1136/ard.2004.030338. 61. Cipriani P., Di Benedetto P., Ruscitti P., Liakouli V., Berardicurti O., Carubbi F., Ciccia F., Guggino G., Zazzeroni F., Alesse E., et al. …

Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management.

Purpose of reviewVEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly discovered, adult-onset, hemato-inflammatory disease driven by clonal dominance of pro-inflammatory hematopoietic cells bearing a somatic mutation in the UBA1 gene. This review aims to integrate and discuss the most recent insights into the evolving understanding of VEXAS pathogenesis and clinical management.Recent findingsAn interplay between inflammation and clonal dominance of UBA1 mutant hematopoietic clones underlies the pathogenesis of VEXAS syndrome. Mutant cells both generate and susta

Совпадение в полном тексте источника
… Ann Rheum Dis 2024; 83:1358–1367. 49. Eviatar T, Sagy I, Campochiaro C, et al. POS0383 IL-1 Inhibition in patients with vexas syndrome – a retrospective international multicenter study. Ann Rheum Dis 2025; 84:627. 50. Mishra R, Calabrese C, Jain AG, Singh A. … Ann Rheum Dis 2025. [Online ahead of print]. Available from: https://www.sciencedirect.com/science/article/pii/S0003496725010398?via%3Dihub [cited 2025 Aug 25] 57. Comont T, Heiblig M, Rivière E, et al. …

The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study.

Biologics are used for ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis (PsA) treatment. The association between biologics and the development of hematologic malignancies is controversial, and data on patients with AS, psoriasis, and PsA are scarce. This retrospective cohort study used data from 2010 to 2020 from Taiwan's National Health Insurance Research Database (NHIRD). Patients with AS, psoriasis, and PsA were divided into a biologics and non biologics group after 1:10 propensity score matching. The hematologic malignancy incidences and the time-/dose-dependent effects on b

Совпадение в полном тексте источника
… Rheum. Dis. 2023;82:3–18. doi: 10.1136/ard-2022-223356. 19. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann. Rheum. Dis. 2010;69:48–53. doi: 10.1136/ard.2008.102053. 20. … Rheum. Dis. 2017;76:105–111. doi: 10.1136/annrheumdis-2016-209270. 30. Nocturne G., Boudaoud S., Ly B., Pascaud J., Paoletti A., Mariette X. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J. …

Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.

PURPOSE OF REVIEW: Recent advances in hematology-oncology have pioneered cell-mediated elimination of pathologic B-cell populations employing chimeric antigen receptor (CAR) T cells. In this review, we discuss recent adoption of CAR-T treatment for severe refractory autoimmune disease. We highlight unique aspects of the autoimmune model and review current clinical data regarding treatment of rheumatologic disease. RECENT FINDINGS: To date, several CAR-Ts are FDA approved for Multiple Myeloma and B-cell malignancies and have demonstrated extraordinary clinical responses in refractory disease. …

Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial.

CD38 is highly expressed on various immune cells, including long-lived plasma cells, making it a potential therapeutic target in autoimmune diseases. This phase Ib/IIa study aimed to explore the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CM313, an anti-CD38 antibody, in patients with systemic lupus erythematosus (SLE). Eligible patients were sequentially enrolled in four ascending dose groups (2, 4, 8, and 16 mg/kg) and randomized 4:1 to receive CM313 or placebo intravenously at days 1, 29, 36, 43, and 50. The primary endpoint was safety, and efficacy was explorato

Совпадение в полном тексте источника
… Rheum. Dis. 82 , 1497–1499 (2023). 20. Roccatello, D. et al. Daratumumab monotherapy for refractory lupus nephritis. Nat. Med. 29 , 2041–2047 (2023). 21. Alexander, T. et al. … Rheum. Dis. 78 , 729–735 (2019). 30. Aringer, M. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78 , 1151–1159 (2019). …

Xerostomia due to systemic disease: a review of 20 conditions and mechanisms.

Xerostomia is a common complaint of nearly half of the elderly population and about one-fifth of younger adults. It causes several signs and symptoms, and compromise oral functions and health-related quality-of-life. Multiple reasons are proposed to describe the etiology of xerostomia such as local factors, psychogenic factors, and systemic diseases. In order to manage xerostomia effectively, identification of the main causality is mandatory. The aim of this review was to present systemic diseases leading to xerostomia with their mechanisms of action. We used various general search engines and

Совпадение в полном тексте источника
… 1980 23 1326 9 7447970 10.1002/art.1780231118 23 D’Arbonneau F1 Ansart S Le Berre R Dueymes M Youinou P Pennec YL Thyroid dysfunction in primary Sjögren's syndrome: A long-term followup study Arthritis Rheum 2003 49 804 9 14673967 10.1002/art.11460 24 Okoje V Obiechina A Aken’Ova Y Orofacial lesions … J Rheumatol 2012 39 809 15 22382336 10.3899/jrheum.111075 57 Hida A Kawabe Y Kawakami A Migita K Tominaga M Nakamura H HTLV-I associated Sjögren's syndrome is aetiologically distinct from anti-centromere antibodies positive Sjögren's syndrome Ann Rheum Dis 1999 58 320 2 10225819 10.1136/ard.58.5.320 …

Role of Proteasomes in Inflammation.

The ubiquitin-proteasome system (UPS) is involved in multiple cellular functions including the regulation of protein homeostasis, major histocompatibility (MHC) class I antigen processing, cell cycle proliferation and signaling. In humans, proteasome loss-of-function mutations result in autoinflammation dominated by a prominent type I interferon (IFN) gene signature. These genomic alterations typically cause the development of proteasome-associated autoinflammatory syndromes (PRAAS) by impairing proteasome activity and perturbing protein homeostasis. However, an abnormal increased proteasomal

Совпадение в полном тексте источника
… Tissue-specific up-regulation of the proteasome subunit β5i (LMP7) in Sjögren’s syndrome Arthritis Rheum. 2006 54 1501 1508 10.1002/art.21782 16646031 113. Krause S. Kuckelkorn U. Dörner T. Burmester G.-R. Feist E. Kloetzel P.-M. … Rheum. Dis. 2006 65 1021 1027 10.1136/ard.2005.045930 16414974 PMC1798250 114. Feist E. Dörner T. Kuckelkorn U. Schmidtke G. Micheel B. Hiepe F. Burmester G.R. Kloetzel P.M. …

Терапевтическое применение иммунобиологии в аутоиммунных и воспаленных заболеваниях.

Иммунобиологика или биологическая экспертиза революционизировали терапевтическую парадигму аутоиммунных и подстрекательских заболеваний путем выборочного целеопределения и модуляции дисрегулированных иммунных путей. По сравнению с обычными широкоспектральными иммунопрепрессантами биологика обеспечивает более конкретный и основанный на механизмах рациональный подход, зачастую связанный с повышением эффективности и сокращением неблагоприятных явлений. В этом обзоре содержится всеобъемлющий обзор репертуара терапевтической биологики, механизмов их действий, важнейших клинических испытаний и клини

Совпадение в аннотации оригинала
Immunobiologics or biologics have revolutionized the therapeutic paradigm of autoimmune and inflammatory diseases by selectively targeting a … d therapeutic impact of these agents across a broad spectrum of immune-mediated diseases, including rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), ankylosing spondylitis, chronic spontaneous urticaria, asthma, ulcerative colitis, Crohn's disease, and other forms of inflammatory bowel disease (IBD). Pharmacodynamic parameters, inclu …

The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs.

Musculoskeletal disorders are characterized by several impairments, including pain, affecting muscles, bones, joints and adjacent connective tissue, resulting in temporary or permanent functional limitations and disability. Musculoskeletal pain is particularly prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. To date, several issues persist about the classification of musculoskeletal pain and its management strategies and resources. The treatment of musculoskeletal pain conditions is complex and often requires a multimodal approach, includin

Совпадение в полном тексте источника
… Ann Rheum Dis 2018 ; 77 : 797 – 807 . 29724726 10.1136/annrheumdis-2017-212662 13 Bruyère O Honvo G Veronese N , et al . … Ann Rheum Dis 2016 ; 75 : 1964 – 1970 . 26882927 10.1136/annrheumdis-2015-208387 PMC5099197 …

Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19.

BackgroundGlomerular diseases (GD) are chronic conditions that often involve immune dysfunction and require immunosuppressive therapy (IST) to control underlying pathogenesis. Unfortunately, such diseases appear to heighten risks of severe outcomes in COVID-19 and predispose to other infections that may be life-threatening. Thus, averting preventable infections is imperative in GD patients.SummaryThe advent of vaccines demonstrated to be safe and efficacious against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has favorably impacted the COVID-19 pandemic epidemiology. However,

Совпадение в полном тексте источника
… Dis 2021 Mar 23 Epub ahead of print 10.1136/annrheumdis-2021-220289 PMC8822300 33757968 51 Mori S Ueki Y Hirakata N Oribe M Hidaka T Oishi K Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis Ann Rheum Dis 2012 71 2006 2010 22887851 10.1136 … 2013 65 (11) 2783 2790 23918413 10.1002/art.38107 75 Neel A Bucchia M Neel M Tilly G Caristan A Yap M Dampening of CD8+ T cell response by B cell depletion therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 2019 Apr 71 (4) 641 650 10.1002/art.40766 30375745 76 Bar-Or …

Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.

Chimeric antigen receptor T cell (CAR-T) therapy, an innovative immune cell therapy, has revolutionized the treatment landscape of haematological malignancies. The past 2 years has witnessed the successful application of CD19-targeting CAR constructs in refractory cases of autoimmune rheumatic diseases, including systemic lupus erythematosus, systemic sclerosis and anti-synthetase syndrome. In comparison with existing B cell depletion therapies, targeting CD19 has demonstrated a more rapid and profound therapeutic effect, enabling drug-free remission with manageable adverse events. These promi…